Repurposing tocilizumab in scleroderma patients may prevent early lung disease
Why SARS-CoV-2 replicates better in the upper respiratory tract
31 March 2021Attention and working memory: Two sides of the same neural coin?
31 March 2021Repurposing tocilizumab in scleroderma patients may prevent early lung disease
Research led by Michigan Medicine’s Scleroderma Program and published in Arthritis & Rheumatology found that tocilizumab, a FDA-approved anti-inflammatory drug used to combat rheumatoid arthritis, can prevent lung disease in patients with systemic sclerosis if detected early enough in the disease course.
